UPDATE : Friday, August 16, 2019
상단여백
Anti-cancer Sutene could cause central nervous system abnormality in fetus by Lee Hye-seon 2019-06-24 11:35
Boryung calls off ￦83-billion supply contract in Jordan by Lee Han-soo 2019-06-21 18:00
MSD’s antibiotic Zerbaxa fails to get insurance coverage by Kim Eun-young 2019-06-21 14:13
‘Customized strategies needed for fast-changing Chinese drug regulation’ by Jeong Sae-im 2019-06-21 14:12
Off-label use of Mabthera Inj. denied by Kim Yun-mi 2019-06-20 15:49
라인
‘Korean cancer researchers have risen to world-class level’ by Kim Yun-mi 2019-06-20 15:04
AbbVie unveils data from upadacitinib phase-3 studies of rheumatoid arthritis by Lee Han-soo 2019-06-19 16:27
Hanmi launches osteoarthritis injection in US by Lee Han-soo 2019-06-19 14:52
Genexine to merge with Toolgen by Lee Han-soo 2019-06-19 14:24
‘Keytruda will become most sold orphan drug worldwide by 2024’ by Kim Yun-mi 2019-06-19 11:11
라인
ABL Bio releases latest data on Parkinson's disease treatment by Lee Han-soo 2019-06-18 17:16
‘Yuhan’s Lazertinib promising as 1st-line therapy for NSCLC’ by Jeong Sae-im 2019-06-18 14:43
LEO Pharma Korea names new CEO by Lee Han-soo 2019-06-18 14:36
SK Biopharmaceutical's sleepiness treatment commercially available in US by Lee Han-soo 2019-06-18 13:42
Korean biosimilars take on original drugs in Europe by Jeong Sae-im 2019-06-17 15:26
라인
AstraZeneca to invest $630 million in Korean biohealth sector by Kim Yun-mi 2019-06-17 11:33
Daewoong to develop hearing loss treatment using ion-channel platform tech by Lee Han-soo 2019-06-14 17:27
Lilly, AbbVie unveil new data for psoriasis treatment at global meet by Lee Han-soo 2019-06-14 14:26
LSK Global PS wins international recognition in clinical data management by Lee Hye-seon 2019-06-13 14:30
‘Many drugs won Chinese approval without review suspension’ by Jeong Sae-im 2019-06-13 11:26
-12345678910-
Stock exchange names Kolon Life Science as administrative issueStock exchange names Kolon Life Science as administrative issue
여백
Most viewed
여백
Opinion
[Reporter’s Notebook] SillaJen should be ashamed of itself
[Reporter’s Notebook] SillaJen should be ashamed of itself
[Column] Drug regulator needs adequate expertise to promote medical devices
[Column] Drug regulator needs adequate expertise to promote medical devices
[Reporter's Notebook] Korean drugmakers should increase presence at global conventions
[Reporter's Notebook] Korean drugmakers should increase presence at global conventions
여백
Back to Top